North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 0.949

-3.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Bogdanoff who wrote (185)	12/26/1997 7:27:00 AM
From: andy harrison	Read Replies (1) of 507

David: I think that it will be different with NVX. The reason is that the DTaP approval sets the stage for the biggest $$$'s. The combo vaccines will be what sets NVX apart from the other companies. In the scheme of thing, the DTaP will be far from the companies largest product. I am looking more towards the menigitis and strep products. I really dont want to guess what will be the reaction to the approval at the exact moment of the approval. I am kind of hoping that it comes before or after market hours. The shorts will try to dampen the NVX news by shorting the stock. If the comes when the market is closed then the bulls will have a chance to plan their strategy will if it comes during the actual market hours, the shorts will probably jump on it. I still believe that in the next 3-5 years, NVX will be doing well over 1 billion in revenues and closing in on 2 billion with the menigitis and strep products coming on-line.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next